

Supporting Information

Synthesis of Novel Vitamin K₂ Analogues with Modification at the ω -Terminal Position and their Biological Evaluation as Potent Steroid and Xenobiotic Receptor (SXR) Agonists

Yoshitomo Suhara, Masato Watanabe, Kimie Nakagawa, Akimori Wada, Yoichi Ito, Kazuyoshi Takeda, Kazuhiko Takahashi, and Toshio Okano


Contents:

I. ¹ H and ¹³ C NMR chart of compound 10 and 11	S2 - S3
II. A comprehensive statement of confirming purity and the method	S4
III. HPLC data of compound 3 - 11 used in biological assays	S5 - S9
IV. Synthetic procedure of compound 15a and 15b	S10


¹H NMR chart of compound **10**



SUMMARY		SPECIAL	
date	NOV 11 1956	swap	not used
account	edc23	gen	not used
file	acq	spcl	16
ACQUISITION			
aw	7396.8	wp39	31,000
ac	3074.4	afca	6,400
fb	4080.1		PLANS
cc	32	in	0
de	5	de	7
el	1,660.4		
ec			PROCESSING
transmitter	2	in	0.26
		cu	5523.6
ta	83		DISPENS
mfrc	499,034	ap	0.0
uapw	88		2700
uapw	88	efl	3806.8
pw	5,584	rfp	0
DECOMPOSITION			
du	C33	lp	-23.7
duf	6		PLAY
du	244	w	2700
du	8	e	8
duw	34	w	126
duf	12404		



10




ME-2-FB
C-13

exp34 Carbon


```

sigl4 carbon
=====
date Nov 11 2012 time not used
swagser edel3 gain 36
file acquisition exp gain 16
=====
sn 30165.9 gw90 39.000
sn 17682.1 gain 19.000
tp 70465 PLANE
sn 13000 k1
sn 12000 k2
cl 10000 k3
cl 9400 k4
sn 3584 ED
=====
TRANSMITTER lb PROCESSING
=====
un 173 fcs not used
un 125 fcs DISCARD
tsp 11050.4 kg -0.0
tsp 83 up 19150.8
pr 6.550 rT1 1915.0
=====
DECODEDUPERS ksp 0
=====
un k1 up -06.3
un k2 up -219.9
un 377 PLCT
dn w w 270
dn 3 w 675
dmf 11200 va 61754
=====
at cdc ph 98

```



10



II. A comprehensive statement of confirming purity and the method

The purity of compound **3-11** was confirmed by following method. The HPLC analyses were conducted with a Shimadzu HPLC system (Simadzu, Kyoto, Japan) consisting of a binary pump (LC-20AD liquid chromatography), an automatic solvent degasser (DGU-20A₃ degasser), and a manual injector. Separations were carried out using a reversed-phase C₁₈ analytical column (COSMOSIL 5C₁₈-AR-II; 4.6 mm i.d. × 250 mm) (Nakalai tesque, Kyoto, Japan) with a solvent system consisting of an isocratic solvent. The solvent contained either methanol, ethanol, or water was delivered at 1.0 mL/min. This mobile phase was passed through the column at 1.0 mL/min. The column was maintained at 40 °C with a column oven (CTO-20A column oven). Vitamin K analogues were detected at 258 nm with an SPD-M20A diode array detector. The HPLC system was controlled by a CBM-20A System Controller (Shimadzu).

Table 1 overview the results of detection and the purity of the compound **3 – 11**. The purity of the each compound was calculated from a surface integral of detected peaks. Those purities were satisfied more than 95%.

Table 1. Results of HPLC detection and purity.

compound	isocratic solvent (v/v)	retention time (min)	purity (%)
3	MeOH / H ₂ O = 90 : 10	6.838	99
4	MeOH / H ₂ O = 95 : 5	7.568	98
5	MeOH / H ₂ O = 95 : 5	11.963	96
6	MeOH	9.115	99
7	MeOH / H ₂ O = 80 : 20	9.760	96
8	MeOH / H ₂ O = 90 : 10	8.273	97
9	MeOH / H ₂ O = 90 : 10	15.604	98
10	MeOH / H ₂ O = 95 : 5	9.334	98
11	MeOH / H ₂ O = 95 : 5	15.406	99

III. HPLC data of compound 3 - 11 used in biological assays

Sample: **3** (MK-1)

Sample Size: 20 μ L (2.1 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 90 : 10, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.9 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 6.838 min

Purity: 99%



Sample: **4** (MK-2)

Sample Size: 20 μ L (3.2 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 95 : 5, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.0 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 7.568 min

Purity: 98%



Sample: **5** (MK-3)

Sample Size: 20 μ L (3.0 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 95 : 5, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.0 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 11.963 min

Purity: 96%



Sample: **6** (MK-4)

Sample Size: 20 μ L (0.9 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.0 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 9.115 min

Purity: 99%



Sample: **7**

Sample Size: 20 μ L (0.2 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 80:20, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 7.9 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 9.760 min

Purity: 96%



Sample: **8**

Sample Size: 20 μ L (0.3 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 90 : 10, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.9 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 8.273 min

Purity: 97%



Sample: 9

Sample Size: 20 μ L (2.0 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 90 : 10, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.9 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 15.604 min

Purity: 98%



Sample: 10

Sample Size: 20 μ L (4.1 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 95 : 5, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.0 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, Retention Time: 9.334 min

Purity: 98%



Sample: **11**

Sample Size: 20 μ L (3.8 mg / 2 mL-EtOH)


Column: 5C₁₈-AR-II (nacalai tesque), 4.6 \times 250 mm

Eluant: MeOH / H₂O = 95 : 5, isocratic flow

Flow Rate: 1.0 mL / min, Press.: 5.0 MPa, Temp.: 40°C

Detection: Ch.1 258 nm, , Retention Time: 15.406 min

Purity: 99%



IV. Experimental method and data of compound **15a** and **15b**

Synthesis of compounds 15a and 15b. Commercially available phenylmagnesium bromide (7.6 mL of a 3.0 M solution, 22.4 mmol) was added dropwise to a mixture of THP ether **14a** (538 mg, 2.12 mmol) or **14b** (684 mg, 2.12 mmol) and copper (I) iodide (1.98 g, 10.4 mmol) in THF (40 mL) with stirring at room temperature. The resulting mixture was heated to 50°C and allowed to stir for 4 h. The reaction was then quenched by addition of saturated NH₄Cl and extracted with ether. Concentration of the combined extracts *in vacuo* provided a yellow oil, which upon purification by flash column chromatography (60: 40 hexanes/ethyl acetate) afforded compound **15a** or **15b** as a colorless oil (**15a**: 368 mg, 76%, **15b**: 443 mg, 70%): The data of **15a** was reported in ref. 17. The data for **15b**: ¹H NMR (500 MHz, CDCl₃) δ 7.28-7.18 (m, 5H), 5.43 (t, 1H, *J*= 1.2 Hz), 5.24 (t, 1H, *J*= 1.2 Hz), 5.13 (t, 1H, *J*= 1.2 Hz), 4.17 (d, 2H, *J*= 6.9 Hz), 3.28 (s, 2H), 2.12-2.04 (m, 8H), 1.69 (s, 3H), 1.61 (s, 3H), 1.54 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 140.4, 140.0, 135.2, 134.3, 129.5, 128.8 (2C), 128.1 (2C), 126.3, 125.8, 123.9, 123.1, 59.4, 46.2, 39.5, 26.8, 26.6, 16.2, 16.0, 15.8; ESI-HRMS (M+H⁺) *m/z* calcd for C₂₁H₃₀O 299.2375. Found 299.2377.